Who Paid My Doc
Michael Dempsey
Endocrinology, Diabetes & Metabolism Rockville, MD Medical Doctor
NPI 1730197229 CMS profile 78988
3200 Tower Oaks Blvd, Suite 250, Rockville, MD 20852
General payments
$4,493
Research payments
$78,131
Ownership & investment interest
$0
Research they led as principal investigator
$2,703,920
Through program year 2024, Michael Dempsey of Rockville, MD is reported in the CMS Open Payments database as having received $4,493 across 33 general payments and $78,131 in research payments paid to them. Separately, studies naming them as principal investigator received $2,703,920 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | Research | $11,000 | 2 | |
| 2023 | Research | $795 | 1 | |
| 2022 | General | $112 | 1 | |
| 2022 | Research | $36,161 | 2 | |
| 2021 | Research | $637 | 3 | |
| 2020 | General | $1,543 | 17 | |
| 2020 | Research | $8,406 | 4 | |
| 2019 | General | $2,839 | 15 | |
| 2019 | Research | $21,132 | 2 |
Beside peers
- Michael Dempsey
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Michael Dempsey were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Michael Dempsey | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,839 | $494 | $123–$2,253 | $163 |
| 2020 | $1,543 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $112 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 37 drugsPart D claims
1,576
Drug cost
$805,317
Branded share of claims
56.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 141 | $258,081 | |
| Jardiance Empagliflozin | Brand | 125 | $167,052 | |
| Mounjaro Tirzepatide | Brand | 84 | $99,336 | |
| Trulicity Dulaglutide | Brand | 30 | $54,116 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 40 | $47,169 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 51 | $37,812 | |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | Brand | 38 | $37,503 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 18 | $17,295 | |
| Synthroid Levothyroxine Sodium | Brand | 148 | $16,378 | |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | Brand | 14 | $13,180 |
The 10 drugs with the highest cost, of 37 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
47 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Maryland
Daniel Gozzi
Endocrinology, Diabetes & Metabolism · Suitland, MD
Martin Sarkar
Endocrinology, Diabetes & Metabolism · Frederick, MD
Nicholas Argento
Endocrinology, Diabetes & Metabolism · Laurel, MD
Romeu Azevedo
Endocrinology, Diabetes & Metabolism · Camp Springs, MD
David Brown
Endocrinology, Diabetes & Metabolism · Rockville, MD
Philip Levin
Endocrinology, Diabetes & Metabolism · Baltimore, MD
Related records
Endocrinology, Diabetes & Metabolism in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.